Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmB1rpmB2rpmCrpmDrpmErpmFrpmG1rpmG2rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsR1rpsR2rpsSrpsTrpsZ
The experimentally established mechanism targets of Sutezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.80 |
| ▸ | SDHA | P31040 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CALML3 | P27482 | 1/20 | 0.80 |
| ▸ | F10 | P00742 | 9/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sutezolid SCHEMBL2152517 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Sutezolid SCHEMBL2152519 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6058545 | 0.94 | MAOA (0.89) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL18396725 | 0.94 | MAOA (0.89) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL18397559 | 0.94 | MAOA (0.89) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6058543 | 0.94 | MAOA (0.89) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL18396727 | 0.94 | MAOA (0.89) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL4178030 | 0.93 | MAOA (0.86) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL4178033 | 0.93 | MAOA (0.86) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6040542 | 0.92 | MAOB (0.85) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4324824-A2 | COMBINATION ANTIBACTERIAL COMPOSITION AND SHORT-COURSE ANTIBACTERIAL REGIMEN | The Global Alliance for TB Drug Development, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230414625-A1 | Combination Antibacterial Composition and Short-Course Antibacterial Regimen | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-3362068-B1 | COMBINATION ANTIBACTERIAL COMPOSITION AND SHORT-COURSE ANTIBACTERIAL REGIMEN COMPRISING LINEZOLID, BEDAQUILINE AND PRETOMANID | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-114796231-A | Combined antimicrobial compositions and short-course antimicrobial regimens | 结核病药物开发全球联盟公司 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414625-A1 | Combination Antibacterial Composition and Short-Course Antibacterial Regimen | PPARD, PEPD, THPO | MAOB 2022/4885MAOA 1686/4885PTGS1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.